What is Insmed's cash & equivalents?

Insmed (INSM) reported cash & equivalents of $582.19M in Q1 2026.

How has Insmed's cash & equivalents changed year-over-year?

Insmed's cash & equivalents increased by 44.4% year-over-year, from $403.25M to $582.19M.

What is the long-term trend for Insmed's cash & equivalents?

Over 5 years (2020 to 2025), Insmed's cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $532.76M to $510.45M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Insmed INSM Cash & Equivalents

Cash & Equivalents at other companies

Sarepta Therapeutics, Inc.SRPT

$464.45M+92.8%

United TherapeuticsUTHR

$1.28B-32.6%

Solid Biosciences Inc.SLDB

$297.1M+41.1%

ANI PharmaceuticalsANIP

$311.21M+108%

Regeneron PharmaceuticalsREGN

$2.97B-4.0%

SavaraSVRA

$38.79M+98.4%

Other financials

Income statement

See full

Revenue$306.0M+230%

Gross profit$258.5M+261%

Operating income-$153.3M+38.2%

Net income-$163.6M+36.3%

EPS (diluted)-$0.76+46.5%

Balance sheet

See full

Total debt$580.3M-49.2%

Total equity$704.9M+611%

Total assets$2.1B+15.2%

Cash flow

See full

Operating cash flow-$222.7M+15.0%

CapEx$3.5M-65.4%

Free cash flow-$226.2M+16.9%

Valuation

See full

Market cap$23.11B+25.2%

Enterprise value$23.11B+29.9%

P/S28.2×-18.2×

Profitability

See full

Gross margin81.8%+5.3pp

Operating margin-140.6%-43.9pp

Net margin-144.4%-45.3pp

FCF margin-112.5%-35.3pp

Returns & leverage

See full

Return on equity-294.5%—

Debt / equity0.8×-10.7×

Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insmed's cash & equivalents?: Insmed (INSM) reported cash & equivalents of $582.19M in Q1 2026.
How has Insmed's cash & equivalents changed year-over-year?: Insmed's cash & equivalents increased by 44.4% year-over-year, from $403.25M to $582.19M.
What is the long-term trend for Insmed's cash & equivalents?: Over 5 years (2020 to 2025), Insmed's cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $532.76M to $510.45M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.